Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab

BACKGROUND: Triple negative breast cancer (TNBC) remains the most challenging breast cancer subtype so far. Specific therapeutic approaches have rarely achieved clinical improvements in treatment of TNBC patients and effective molecular biomarkers are largely unknown. METHODS: We used paired TNBC sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jie, Ma, Maoguang, Yang, Xuesong, Zhang, Maolei, Luo, Jingyan, Zhou, Huangkai, Huang, Nunu, Xiao, Feizhe, Lai, Bingquan, Lv, Weiming, Zhang, Nu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488427/
https://www.ncbi.nlm.nih.gov/pubmed/32917240
http://dx.doi.org/10.1186/s12943-020-01259-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488427/
https://www.ncbi.nlm.nih.gov/pubmed/32917240
http://dx.doi.org/10.1186/s12943-020-01259-6

Ejemplares similares